Mohan Bala compensation by year
Mersana Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $414,000 | $430,500 | $470,000 |
| Bonus | $62,800 | $0 | $0 |
| Stock awards | $205,668 | $269,100 | $176,166 |
| Option awards | $192,510 | $762,804 | $682,920 |
| Non-equity incentive | $7,000 | $111,930 | $166,850 |
| Pension and deferred compensation | — | $0 | $0 |
| All other | — | $7,000 | $7,000 |
| Total | $874,978 | $1,581,334 | $1,502,936 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mersana Therapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001104659-25-040448, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Mersana Therapeutics, Inc. filed document, accession 0001104659-25-040448. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 58,333 | $83,416 | — |
| RSU | 26,250 | $37,538 | — |
| RSU | 6,250 | $8,938 | — |
| Option | 88,594 | — | $6.06 |
| Option | 213,281 | — | $3.02 |
| Option | 28,125 | — | $8.63 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Mersana Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
15 Form 4 lines since the FY2024 proxy (filed April 29, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-01-06 | U | — | 2,927 | — | 0 |
| 2026-01-06 | Disposition to the issuer derivative | — | 7,734 | — | 0 |
| 2026-01-06 | Disposition to the issuer derivative | — | 5,246 | — | 0 |
| 2026-01-06 | Disposition to the issuer derivative | — | 1,053 | — | 0 |
| 2026-01-06 | Disposition to the issuer derivative | — | 1,190 | — | 0 |
| 2026-01-06 | Disposition to the issuer derivative | — | 9,309 | — | 0 |
| 2026-01-06 | Disposition to the issuer derivative | — | 700 | — | 0 |
| 2026-01-06 | Disposition to the issuer derivative | — | 1,853 | — | 0 |
The 8 most recent of 15 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Mersana Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Martin Huber | President and Chief Executive Officer | $1,613,754 |
| Brian DeSchuytner | Senior Vice President, Chief Operating Officer and Chief Financial Officer | $1,543,586 |
| Mohan Bala · this page | Senior Vice President, Chief Development Officer | $1,502,936 |
| Timothy Lowinger | Senior Vice President, Chief Science and Technology Officer | $1,400,535 |
| Alejandra Carvajal | Senior Vice President, Chief Legal Officer | $1,359,885 |
Mohan Bala's compensation dossier, Mersana Therapeutics
You have read Mohan Bala's totals and holdings. The dossier adds each equity grant Mersana Therapeutics disclosed for Mohan Bala and Mersana Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Mersana Therapeutics compensation record
free company briefThis page is one person within Mersana Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Mersana Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Mersana Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mersana Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order MRSN
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.